153SM-EDTMP

153SM-EDTMP Uses, Dosage, Side Effects, Food Interaction and all others data.

Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium Sm 153 lexidronam is used to help relieve the bone pain that may occur with certain kinds of cancer. The radioactive samarium is taken up in the bone cancer area and gives off radiation that helps provide relief of pain.

153SM-EDTMP
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	153SM-EDTMP
Generic	Samarium (153Sm) lexidronam
Samarium (153Sm) lexidronam Other Names	153SM-EDTMP, Samarium (153 Sm) lexidronam, Samarium (153Sm) lexidronam, Samarium Sm-153 lexidronam, Samarium-153 lexidronam, Samarium-153-EDTMP
Type
Formula	C₆H₁₇N₂O₁₂P₄Sm
Weight	Average: 586.021 Monoisotopic: 585.895290894
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

153SM-EDTMP is a chelated complex of samarium isotope and EDTMP that concentrates in areas with high bone turnover such as sites of metastases to relieve pain associated with osteoblastic metastatic bone lesions.

Investigated for use/treatment in bone metastases, multiple myeloma, prostate cancer, and rheumatoid arthritis.

153SM-EDTMP is also used to associated treatment for these conditions: Bone pain

How 153SM-EDTMP works

Samarium Sm 153 lexidronam targets the sites of new bone formation, concentrating in regions of the bone that have been invaded with metastatic tumor. The drug goes to the source of cancer bone pain and irradiates the osteoblastic tumor sites resulting in relief of pain. The onset of pain relief was experienced as early as one week in the majority of patients.